Experimental immune therapy aims to tame severe transplant complication
NCT ID NCT06920199
First seen Sep 30, 2025 · Last updated May 23, 2026 · Updated 23 times
Summary
This early-stage trial tests a new treatment for people with chronic graft-versus-host disease (cGVHD) that hasn't responded to standard steroids. The treatment uses special immune cells (Treg cells) from the original stem cell donor, combined with a low dose of interleukin-2, to try to control the overactive immune response. The main goal is to check safety and find the right dose in 18 adults aged 18-70.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, 200080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.